<DOC>
	<DOCNO>NCT02412345</DOCNO>
	<brief_summary>The primary objective study determine impact shock wave application renal transplant patient diagnosis erectile dysfunction . Secondary objective assess effect therapy quality life depression . It expect study define usefulness therapy dissemination knowledge generate change clinical management renal transplant patient erectile dysfunction .</brief_summary>
	<brief_title>Extracorporeal Shockwave Therapy Treatment Erectile Dysfunction Male Renal Transplant Recipients</brief_title>
	<detailed_description>The Renal Transplant Unit , perform 230 kidney transplant per year screening service registration candidate renal transplantation , interview 70 patient month . Since potential likely benefit extracorporeal shock wave therapy patient well anticipation mild side effect , reason refusal participate study . Patients meet inclusion criterion divide 2 group use randomization table create computer . Patients follow 2 year . The study procedure monitoring perform outpatient basis . Patients divide group extracorporeal shockwave ( ESWT ) treatment placebo ratio 1 : 1 use table random number generate computer . The ESWT protocol protocol-based suggest Vardi et al . 6 . Patients undergo 2 treatment session per week 3 week . The penis pull manually , shock wave apply throughout penile shaft ( except glans ) crura bilaterally . The duration ESWT session approximately 10 minute 2000 shock apply per session intensity energy 1 mJ / mm 2 . The volume penile tissue expose shock wave site cilyndric ( diameter : 18 mm , height 100 mm ) . No local systemic analgesia require procedure . To placebo therapy use device . The effective probe replace similar one emits zero energy treatment . Local application generates noise feel pop application site also experience patient placebo group impossible patient discern treatment group belong . Penile ultrasound Doppler drug erection perform therapy treatment evaluate result . The diameter cavernous artery measure intracavernosal injection application 20 mcg alprostadil ( Caverject Â® ) . In addition , vascular disorder , stenotic atheromatous lesion investigate . The systolic diastolic velocity cavernous artery evaluate 5,10 15 minute drug injection . After obtain patient sign informed consent , include study . Laboratory test hold Hospital Laboratory . Studied variables The following parameter study initial evaluation follow-up : 1 . Clinical Quality life questionnaire -WHO QOL ( World Health Organization - Quality Life ) Sexual questionnaire IIEF ( International Index Erectile Function ) Comorbidities hypertension , diabetes cardiovascular disease Smoking 2 . Laboratory Total testosterone , free testosterone , progesterone , albumin , SHBG , FSH , LH , prolactin , complete blood count , urea , creatinine , total cholesterol fraction , triglyceride , T3 , T4F TSH . 3 . Imaging test Ultrasound Doppler penile 3 month treatment . - Calculation sample To define sample size , investigator must take account : data variability ( within group ) difference investigator want observe parameter study treatment , beyond level significance power test . The investigator assume data follow normal distribution use pair t-test methodology , consider patient evaluated condition . The level significance work 5 % . Suitable power consider great 80 % . The investigator observe difference 5 point required amount sample small , whereas 3 patient t-test . non-parametric test consider sample 4 patient .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>Male patient 40 70 year Kidney transplant least 6 month Erectile dysfunction ( ED ) least 6 month . Patients IIEF score &lt; 21 Functioning kidney graft . ED known endocrine disease ( e.g. , hypogonadism , hypothyroidism ) ED due drug treatment ( androgen deprivation therapy , example ) ED due neurological disease ( spinal cord injury , example ) ED due structural abnormality penis History radical prostatectomy pelvic surgery History pelvic irradiation penile implant coagulopathies anticoagulant</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Shockwave therapy</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Male</keyword>
	<keyword>Renal Transplant Recipients</keyword>
</DOC>